DiscoverThe Chain: Protein Engineering PodcastEpisode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond
Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

Update: 2024-10-16
Share

Description

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more.  

LINKS:
Bionavigen
ImmunoGen 

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

Cambridge Healthtech Institute